Current status of amyloid-targeting immunotherapies for Alzheimer's disease

被引：9
|
作者：
Tabor, G. Travis [1 ,2 ,3 ]
Holtzman, David M. [1 ,2 ]
机构：
[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA
[2] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63130 USA
[3] Washington Univ, Sch Med, Med Scientist Training Program, St Louis, MO USA
来源：
SCIENCE TRANSLATIONAL MEDICINE | 2023年 / 15卷 / 721期
关键词：
D O I：
10.1126/scitranslmed.adk9993
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer's disease. Anti-amyloid antibodies are moving from clinical trials into patients to treat early clinical stages of Alzheimer's disease.
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Translational opportunities for amyloid-targeting fluorophores
    Cao, Kevin J.
    Yang, Jerry
    CHEMICAL COMMUNICATIONS, 2018, 54 (66) : 9107 - 9118
  • [22] Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update
    Yadollahikhales, Golnaz
    Rojas, Julio C.
    NEUROTHERAPEUTICS, 2023, 20 (04) : 914 - 931
  • [23] Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
    Golnaz Yadollahikhales
    Julio C. Rojas
    Neurotherapeutics, 2023, 20 : 914 - 931
  • [24] Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease
    Liu, Kathy Y.
    Villain, Nicolas
    Ayton, Scott
    Ackley, Sarah F.
    Planche, Vincent
    Howard, Robert
    Thambisetty, Madhav
    BRAIN COMMUNICATIONS, 2023, 5 (03)
  • [25] Targeting β-amyloid pathology in Alzheimer's disease with Aβ immunotherapy
    Nitsch, Roger M.
    Hock, Christoph
    NEUROTHERAPEUTICS, 2008, 5 (03) : 415 - 420
  • [26] Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
    Chenghuan Song
    Jiyun Shi
    Pingao Zhang
    Yongfang Zhang
    Jianrong Xu
    Lanxue Zhao
    Rui Zhang
    Hao Wang
    Hongzhuan Chen
    Translational Neurodegeneration, 11
  • [27] Targeting β-amyloid pathology in Alzheimer’s disease with Aβ immunotherapy
    Roger M. Nitsch
    Christoph Hock
    Neurotherapeutics, 2008, 5 : 415 - 420
  • [28] Immunotherapy for Alzheimer's disease: targeting β-amyloid and beyond
    Song, Chenghuan
    Shi, Jiyun
    Zhang, Pingao
    Zhang, Yongfang
    Xu, Jianrong
    Zhao, Lanxue
    Zhang, Rui
    Wang, Hao
    Chen, Hongzhuan
    TRANSLATIONAL NEURODEGENERATION, 2022, 11 (01)
  • [29] Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement
    Rentz, Dorene M.
    Aisen, Paul S.
    Atri, Alireza
    Hitchcock, Janice
    Irizarry, Michael
    Landen, Jaren
    Matthews, Brandy R.
    Miller, David S.
    Mahinrad, Simin
    Napoli, Salvatore
    Okhravi, Hamid R.
    Petersen, Ronald C.
    Siemers, Eric R.
    Weber, Christopher J.
    Weisman, David C.
    Carrillo, Maria C.
    ALZHEIMERS & DEMENTIA, 2024, 20 (11) : 8162 - 8171
  • [30] Discordant Amyloid Status Diagnosis in Alzheimer's Disease
    Garcia-Valles, Lorena
    Pena-Bautista, Carmen
    Alvarez-Sanchez, Lourdes
    Ferrer-Cairols, Ines
    Baquero, Miguel
    Chafer-Pericas, Consuelo
    BIOMEDICINES, 2022, 10 (11)
12345